Alison Tanchyk

She represented General Cable Corporation in connection with an FCPA investigation of General Cable’s business operations in Angola, Portugal, China, Egypt, and Thailand, resulting in a non-prosecution agreement and no compliance monitor. She also represented Olympus Corporation of the Americas in connection with an FCPA investigation of Olympus’s sales and marketing practices in Latin America resulting in a deferred prosecution agreement.

Since 2014, she has repeatedly been named by Latinvex as one of Latin America’s top Female Lawyers and was most recently named in 2023.

Alison is also the co-leader of the Florida Chapter of the Women’s White Collar Defense Association.

Results may vary depending on your particular facts and legal circumstances.

Anticorruption

• General Cable Corporation in DOJ and SEC FCPA investigations of the company’s business operations in Angola, Portugal, China, Egypt, and Thailand.
• Olympus Corporation of the Americas in an FCPA investigation of their sales and marketing practices in Latin America. Resulted in a deferred prosecution agreement and $22.8 million fine.
• Key government witness in United States v. McDonnell Virginia corruption trial.
• A Fortune 100 company in an FCPA internal investigation in Korea and China involving related inquiries by the U.S. Department of Justice and Securities and Exchange Commission.
• A Fortune 100 company in an FCPA internal anticorruption and anti-competition investigation in Vietnam and Singapore and related inquiries by the World Bank.
• Corporations in FCPA and foreign anti-corruption laws internal investigations in Russia, Asia, Africa, Eastern Europe, Central America, and South America.

Antitrust

• Multiple corporations in federal civil antitrust actions involving, inter alia, allegations of price fixing.
• Declination of prosecution of corporation in a federal criminal antitrust action involving, inter alia, allegations of price fixing and bid-rigging.

Healthcare Fraud and Abuse

• Cross-border healthcare fraud internal investigation involving allegations of fraudulent billing and bid-rigging.
• Pharmaceutical manufacturers in connection with DOJ criminal and civil investigations involving allegations of, inter alia, off-label marketing.
• A pharmaceutical manufacturer in non-intervened Qui Tam litigations
• Individuals in a DOJ investigation involving allegations of, inter alia, Anti-Kickback Statute, and health care fraud violations.
• A pharmaceutical manufacturer in internal investigation of its contracting protocols and procedures in its selection and use of a clinical study investigator.
• Healthcare provider owners in connection with DOJ criminal and civil investigation of alleged conspiracy to commit healthcare fraud and money laundering.

Results may vary depending on your particular facts and legal circumstances.